Stay updated on Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer now shows site revision v3.8.0 instead of v3.7.2; the study record content remains unchanged.
    Difference
    0.1%
    Check dated 2026-11-02T15:45:50.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    A banner announces NIH website transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    0.4%
    Check dated 2026-10-26T15:49:58.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-19T21:52:48.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-13T04:23:13.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    - A new revision entry v3.7.0 appears in the study record history. The previous v3.6.6 entry is removed from the history list, indicating an update to the page's revision tracking.
    Difference
    0.1%
    Check dated 2026-09-21T22:22:09.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Revision: v3.6.6 is now shown, replacing Revision: v3.6.5. This signals a new build of the page rather than any substantive content change.
    Difference
    0.1%
    Check dated 2026-08-31T17:30:23.000Z thumbnail image

Stay in the know with updates to Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.